These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28487611)

  • 21. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
    Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
    J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus.
    Miyata H; Doki Y; Yasuda T; Yamasaki M; Higuchi I; Makari Y; Matsuyama J; Hirao T; Takiguchi S; Fujiwara Y; Monden M
    Dis Esophagus; 2008; 21(2):144-50. PubMed ID: 18269650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer screening of asymptomatic individuals using 18F-FDG PET/CT in China: a retrospective study.
    Tong J; Zou Y; Jiang J; Shi W; Tao R; Ye J; Lu Y; Jiang X; Wang W
    Discov Med; 2016 Oct; 22(121):181-188. PubMed ID: 27875669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of FDG-PET for detecting multiple primary cancers in hypopharyngeal cancer patients.
    Kaida H; Ishibashi M; Kurata S; Uchiyama Y; Tanaka N; Abe T; Kobayashi M; Kaibara H; Uchida M; Nakashima T; Fujita H; Hayabuchi N
    Nuklearmedizin; 2009; 48(5):179-84. PubMed ID: 19639163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
    Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer.
    Keswani RN; Early DS; Edmundowicz SA; Meyers BF; Sharma A; Govindan R; Chen J; Kohlmeier C; Azar RR
    Gastrointest Endosc; 2009 Jun; 69(7):1210-7. PubMed ID: 19012886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer.
    Hu Q; Wang W; Zhong X; Yuan S; Fu Z; Guo H; Yu J
    Eur J Radiol; 2009 May; 70(2):320-4. PubMed ID: 18602239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
    Flamen P; Lerut A; Van Cutsem E; Cambier JP; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
    Makino T; Doki Y; Miyata H; Yasuda T; Yamasaki M; Fujiwara Y; Takiguchi S; Higuchi I; Hatazawa J; Monden M
    Surgery; 2008 Nov; 144(5):793-802. PubMed ID: 19081023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer.
    Yuan S; Yu Y; Chao KS; Fu Z; Yin Y; Liu T; Chen S; Yang X; Yang G; Guo H; Yu J
    J Nucl Med; 2006 Aug; 47(8):1255-9. PubMed ID: 16883002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of ¹⁸F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma.
    Yasuda T; Higuchi I; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Hatazawa J; Doki Y
    Ann Surg Oncol; 2012 Feb; 19(2):652-60. PubMed ID: 21769466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.
    Minamimoto R; Senda M; Terauchi T; Jinnouchi S; Inoue T; Iinuma T; Inoue T; Ito K; Iwata H; Uno K; Oku S; Oguchi K; Tsukamoto E; Nakashima R; Nishizawa S; Fukuda H; Murano T; Yoshida T
    Ann Nucl Med; 2011 Jan; 25(1):45-54. PubMed ID: 20953985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography.
    Chang JT; Chan SC; Yen TC; Liao CT; Lin CY; Lin KJ; Chen IH; Wang HM; Chang YC; Chen TM; Kang CJ; Ng SH
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):501-7. PubMed ID: 15890593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.